

Llais
Adeiladau'r Goron
Parc Cathays
Caerdydd
CF10 3NQ

Llais
Crown Buildings
Cathays Park
Cardiff
CF10 3NQ



17 September 2026

Mabon ap Gwynfor MS
Cabinet Minister for Health and Care
Welsh Government

Sent via email only to: Correspondence.Mabon.apGwynfor@gov.wales

Dear Cabinet Minister

Access to Enhertu for people in Wales with HER2-Low Advanced Breast Cancer

I write following today's announcement that people in England with HER2-low advanced breast cancer will now have access to Enhertu (trastuzumab deruxtecan) through the NHS after a successful agreement on pricing and a positive recommendation from NICE.

This news will be welcomed by many people affected by advanced breast cancer. The evidence demonstrating improved progression-free survival and extended overall survival offers genuine hope to those facing an incurable diagnosis and additional precious time with their families and loved ones.

As the national independent body giving people a stronger voice in health and social care in Wales, Llais is keen to understand the implications of this announcement for people in Wales.

Cadeirydd / Chair: **Athro / Professor Medwin Hughes DL**

Prif Weithredwr / Chief Executive: **Alyson Thomas**

E-bost / E-mail: **enquiries@llaiscymru.org**

Ffôn / Tel: **02920 235558**

We know that for those living with HER2 breast cancer, their families and advocates will be asking when this treatment will become routinely available through NHS Wales and whether people here will have timely access to the same life-extending treatment now being made available in England.

We would welcome clarification on:

- Whether the Welsh Government intends to adopt the NICE recommendation for Enhertu in Wales.
- The anticipated timescale for any review, approval and implementation process within NHS Wales.
- When eligible patients can expect to begin accessing the treatment.
- What steps are being taken to make sure that people in Wales are not disadvantaged or experience unnecessary delays compared with people elsewhere in the UK.

The announcement has already generated significant public interest, and we expect that people living with advanced breast cancer, along with their families, will be seeking reassurance that they will not receive less favourable treatment because of where they live.

It is important that people in Wales are kept informed about the expected timeline and the actions being taken to secure fair access to effective and innovative treatments. Clear communication on this matter would help provide certainty to those directly affected by this diagnosis at what is already an extremely challenging time in their lives.

We would be grateful for your response and would welcome any information you are able to share regarding the next steps for Wales.

Yours sincerely

A handwritten signature in dark ink, reading 'J A Thomas', with a horizontal line underneath.

Alyson Thomas
Chief Executive

Cadeirydd / Chair: **Athro / Professor Medwin Hughes DL**

Prif Weithredwr / Chief Executive: **Alyson Thomas**

E-bost / E-mail: **enquiries@llyllyscymru.org**

Ffôn / Tel: **02920 235558**

Croesewir gohebiaeth yn y Gymraeg a'r Saesneg. Os byddwch yn ysgrifennu atom yn Gymraeg, byddwn yn ateb yn Gymraeg. Ni fydd hyn yn arwain at oedi wrth ymateb i'ch gohebiaeth.

We welcome correspondence in Welsh and English. If you write to us in Welsh, we will answer in Welsh. This will not lead to a delay in responding to your correspondence.

Cadeirydd / Chair: **Athro / Professor Medwin Hughes DL**

Prif Weithredwr / Chief Executive: **Alyson Thomas**

E-bost / E-mail: **enquiries@llaiscymru.org**

Ffôn / Tel: **02920 235558**